A novel formulation of solubilised amphotericin B designed for ophthalmic use
Authors:
- D.R. SerranoDSD.R. Serrano
- H.K. Ruiz-SaldañaHRH.K. Ruiz-Saldaña
- G. MoleroGMG. Molero
- M.P. BallesterosMBM.P. Ballesteros
- J.J. TorradoJTJ.J. Torrado
- 1 November 2012
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 437 (1-2) , 80-82
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- CDs as solubilizers: Effects of excipients and competing drugsInternational Journal of Pharmaceutics, 2009
- Development of Effective Ocular Preparations of Antifungal AgentsJournal of Ocular Pharmacology and Therapeutics, 2008
- Effect of aggregation state on the toxicity of different amphotericin B preparationsInternational Journal of Pharmaceutics, 2008
- Amphotericin B Formulations and Drug TargetingJournal of Pharmaceutical Sciences, 2008
- HPLC assay for determination of amphotericin B in biological samplesBiomedical Chromatography, 2007
- Liposomal amphotericin B eye drops to treat fungal keratitis: Physico-chemical and formulation stabilityInternational Journal of Pharmaceutics, 2007
- Amphotericin B Molecular Organization as an Essential Factor to Improve Activity/Toxicity Ratio in the Treatment of Visceral LeishmaniasisJournal of Drug Targeting, 2004
- Fungal infections of the corneaEye, 2003
- Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eyeActa Ophthalmologica Scandinavica, 2002
- Cyclodextrins in ophthalmic drug deliveryAdvanced Drug Delivery Reviews, 1999